Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate (S1P) receptor modulator presented as an oral formulation for oral use. It is indicated for relapsing forms of multiple sclerosis and related disease courses in adult patients.

GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Inzolfi (fingolimod) is used in the management of multiple sclerosis, a chronic autoimmune disease of the central nervous system.

- Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression. - Clinically isolated syndrome: delays conversion to definitive multiple sclerosis. - Secondary progressive multiple sclerosis with active disease: lowers relapse activity and may slow worsening of disability.

Fingolimod may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Diarrhea - Nausea - Fatigue

Serious or Rare Side Effects: - Cardiac arrhythmia (including bradycardia) - Severe infections (e.g., opportunistic infections) - Macular edema

When prescribing Inzolfi, several safety considerations should be observed.

- Cardiac monitoring: perform baseline ECG and monitor heart rate after the first dose. - Liver function: assess hepatic enzymes before initiation and periodically during therapy. - Vaccination: avoid live vaccines while receiving treatment. - Pregnancy: contraindicated; ensure effective contraception for women of childbearing potential. - Store at below 25°C: keep in the original packaging, protect from moisture.

Fingolimod can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent use with other S1P receptor modulators: may cause additive immunosuppression. - Strong CYP4F2 inhibitors (e.g., amiodarone): can increase fingolimod plasma levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask bradycardia after the first dose. - Antihypertensive agents: may enhance blood‑pressure‑lowering effects. - Live attenuated vaccines: increased risk of infection due to immunosuppression.